Galera Therapeutics, Inc. (GRTX)

USD 0.03

(-2.17%)

Market Cap (In USD)

1.46 Million

Revenue (In USD)

-

Net Income (In USD)

-59.08 Million

Avg. Volume

320.26 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.021-0.29
PE
-
EPS
-
Beta Value
1.988
ISIN
US36338D1081
CUSIP
36338D108
CIK
1563577
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. J. Mel Sorensen M.D.
Employee Count
-
Website
https://www.galeratx.com
Ipo Date
2019-11-07
Details
Galera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule superoxide dismutase mimetic, which has completed Phase III clinical trial for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); in Phase IIa clinical trial for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and in Phase IIa clinical trial for patients with HNC undergoing standard-of-care radiotherapy. It is also involved in developing GC4711, a superoxide dismutase mimetic product candidate, which is in Phase I/II clinical trial in combination with stereotactic body radiation therapy (SBRT) in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.